NasdaqGS - Nasdaq Real Time Price USD

Taysha Gene Therapies, Inc. (TSHA)

2.7900

+0.0100

+(0.36%)

At close: June 4 at 4:00:00 PM EDT

Taysha Gene Therapies Announces Details for Oral Presentations at the 2025 IRSF Rett Syndrome Scientific Meeting Reviewing Recent Updates from the TSHA-102 Clinical Program

Recently disclosed clinical cohort data from high (1x1015 total vg) and low dose (5.7x1014 total vg) TSHA-102 from REVEAL adolescent/adult and pediatric Phase 1/2 trials Caregiver research regarding gain/regain of developmental milestones supporting alignment with FDA on primary endpoint in the pivotal Part B trial of TSHA-102 Previously disclosed preclinical data supporting broad biodistribution across brain and spinal cord regions following lumbar intrathecal delivery of AAV9 gene therapy vect

GlobeNewswire yesterday

TSHA
+0.36%
Taysha Gene Therapies, Inc. (TSHA)’s TSHA-102 Shows Promising Results in Rett Syndrome Patients Aged 6+

Taysha Gene Therapies, Inc. (NASDAQ:TSHA) has announced pivotal progress in its TSHA-102 gene therapy program for Rett syndrome, following written alignment with the FDA on a single-arm, open-label pivotal trial targeting patients aged six and older. This population, shown by natural history data to have virtually zero chance of regaining developmental milestones, saw a 100% […]

Insider Monkey 7 days ago

TSHA
+0.36%
Taysha Gene Therapies Announces Pricing of Public Offering of Common Stock and Pre-Funded Warrants

DALLAS, May 28, 2025 (GLOBE NEWSWIRE) -- Taysha Gene Therapies, Inc. (Nasdaq: TSHA) (Taysha or the Company), a clinical-stage biotechnology company focused on advancing adeno-associated virus (AAV)-based gene therapies for severe monogenic diseases of the central nervous system (CNS), today announced the pricing of an underwritten public offering of 46,868,687 shares of its common stock at a price to the public of $2.75 per share and, in lieu of common stock to certain investors that so choose,

GlobeNewswire 7 days ago

TSHA
+0.36%
Taysha Gene Therapies Announces Proposed Public Offering of Common Stock and Pre-Funded Warrants

DALLAS, May 28, 2025 (GLOBE NEWSWIRE) -- Taysha Gene Therapies, Inc. (Nasdaq: TSHA) (Taysha or the Company), a clinical-stage biotechnology company focused on advancing adeno-associated virus (AAV)-based gene therapies for severe monogenic diseases of the central nervous system (CNS), today announced that it has commenced an underwritten public offering of shares of its common stock and, in lieu of common stock to certain investors that so choose, pre-funded warrants to purchase shares of its co

GlobeNewswire 7 days ago

TSHA
+0.36%
Taysha Gene Therapies Announces Pivotal Part B Trial Design Details for TSHA-102 in Rett Syndrome Enabled by IRSF Natural History Data and Positive Clinical Data from Part A of the REVEAL Adult/Adolescent and Pediatric Trials Evaluating TSHA-102

Natural history data analysis established patients ≥ six years of age are in developmental plateau, with a ~0% likelihood of gaining/regaining developmental milestones across the core functional domains of Rett syndrome Written alignment from FDA supports single-arm, open label pivotal trial with primary endpoint of developmental milestone gain/regain in the developmental plateau population (≥ 6 years, intend N=15) with each patient serving as their own control 100% of patients in REVEAL Part A

GlobeNewswire 7 days ago

TSHA
+0.36%
Taysha Gene Therapies Inc (TSHA) Q1 2025 Earnings Call Highlights: Promising Clinical Progress ...

Taysha Gene Therapies Inc (TSHA) reports significant advancements in their Rett syndrome program, despite ongoing financial hurdles.

GuruFocus.com 20 days ago

TSHA
+0.36%
Taysha Gene Therapies, Inc. (TSHA) Reports Q1 Loss, Tops Revenue Estimates

Taysha Gene Therapies (TSHA) delivered earnings and revenue surprises of 0% and 9.62%, respectively, for the quarter ended March 2025. Do the numbers hold clues to what lies ahead for the stock?

Zacks 20 days ago

TSHA
+0.36%
Taysha Gene Therapies Reports First Quarter 2025 Financial Results and Provides Corporate Update

Obtained written alignment from the FDA on key elements of TSHA-102 pivotal Part B trial design and next steps on enabling study initiation The FDA advised the Company to submit pivotal Part B trial protocol and associated statistical analysis plan as an amendment to the IND application, eliminating the need for formal end-of-phase meeting and potentially expediting study initiation and registration; IND amendment submission expected in Q2 2025 High dose and low dose of TSHA-102 continue to be g

GlobeNewswire 20 days ago

TSHA
+0.36%
Taysha Gene Therapies to Release First Quarter 2025 Financial Results and Host Conference Call and Webcast on May 15

DALLAS, May 08, 2025 (GLOBE NEWSWIRE) -- Taysha Gene Therapies, Inc. (Nasdaq: TSHA), a clinical-stage biotechnology company focused on advancing adeno-associated virus (AAV)-based gene therapies for severe monogenic diseases of the central nervous system (CNS), today announced that it will report its financial results for the first quarter ended March 31, 2025, and host a corporate update conference call and webcast on Thursday, May 15, 2025, at 8:30 AM Eastern Time. Conference Call DetailsThurs

GlobeNewswire 27 days ago

TSHA
+0.36%
Will Taysha Gene Therapies, Inc. (TSHA) Report Negative Q1 Earnings? What You Should Know

Taysha Gene Therapies (TSHA) doesn't possess the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.

Zacks 29 days ago

TSHA
+0.36%
Assembly Biosciences (ASMB) Soars 24.0%: Is Further Upside Left in the Stock?

Assembly Biosciences (ASMB) was a big mover last session on higher-than-average trading volume. The latest trend in earnings estimate revisions might not help the stock continue moving higher in the near term.

Zacks 30 days ago

ASMB

TSHA
+0.36%
Taysha Gene Therapies Announces Inducement Grant Under Nasdaq Listing Rule 5635(c)(4)

DALLAS, May 02, 2025 (GLOBE NEWSWIRE) -- Taysha Gene Therapies, Inc. (Nasdaq: TSHA) (Taysha or the Company), a clinical-stage biotechnology company focused on advancing adeno-associated virus (AAV)-based gene therapies for severe monogenic diseases of the central nervous system (CNS), today announced that, on May 1, 2025, the Compensation Committee of Taysha's Board of Directors granted one new employee an option to purchase 45,000 shares of the Company's common stock in connection with their em

GlobeNewswire last month

TSHA
+0.36%
Discover Fractyl Health And 2 More Promising Penny Stocks

Over the last 7 days, the United States market has dropped 4.4%, yet earnings are forecast to grow by 13% annually. For those looking to invest in smaller or newer companies, penny stocks can still offer surprising value despite their somewhat outdated name. With solid financial foundations, these stocks have the potential to outperform while offering greater stability, making them intriguing options for investors seeking under-the-radar opportunities with long-term potential.

Simply Wall St. last month

FDMT

TSHA
+0.36%

GUTS
Biotech stocks slide as Marks resignation seen being negative for sector

Shares of several biotech and biopharma names are under pressure on Monday following the resignation of the head of the Food and Drug Administration’s Center for Biologics Evaluation and Research, Peter Marks. RBC Capital says the development is “not good for the biotech industry even beyond vaccines.” Voicing a similar opinion, BMO Capital told investors this morning that it sees the news as a “significant negative” for the biopharma and biotech sectors. “NOT GOOD” FOR BIOTECH SECTOR: RBC Capit

TipRanks 2 months ago

GLPG

GLPGF

PTCT
Is Taysha Gene Therapies (TSHA) the Best Short Squeeze Stock to Buy According to Analysts?

We recently shared a list of 10 Best Short Squeeze Stocks To Buy According to Analysts. In this article, we will see how Taysha Gene Therapies, Inc. (NASDAQ:TSHA) compares to the other top short squeeze stocks that have received a Buy rating from analysts. Stock market trading has an ever-changing environment. Short squeeze is among […]

Insider Monkey 2 months ago

TSHA
+0.36%
Nano Dimension And 2 Other Penny Stocks To Watch Now

As the U.S. stock market faces volatility with tech stocks leading a sell-off amid tariff concerns, investors are searching for opportunities that may offer potential growth despite uncertain conditions. Penny stocks, although an outdated term, continue to represent smaller or newer companies that can provide value at lower price points. By focusing on those with strong financial foundations and promising growth prospects, investors might find hidden gems among these often overlooked stocks.

Simply Wall St. 2 months ago

PRTS

TSHA
+0.36%

NNDM
Taysha Gene Therapies Full Year 2024 Earnings: Beats Expectations

Taysha Gene Therapies ( NASDAQ:TSHA ) Full Year 2024 Results Key Financial Results Net loss: US$89.3m (loss narrowed by...

Simply Wall St. 3 months ago

TSHA
+0.36%
Taysha Gene Therapies, Inc. (TSHA) Reports Q4 Loss, Tops Revenue Estimates

Taysha Gene Therapies (TSHA) delivered earnings and revenue surprises of 12.50% and 6.42%, respectively, for the quarter ended December 2024. Do the numbers hold clues to what lies ahead for the stock?

Zacks 3 months ago

TSHA
+0.36%
Taysha Gene Therapies Reports Full-Year 2024 Financial Results and Provides Corporate Update

High dose and low dose of TSHA-102 continue to be generally well tolerated with no treatment-related SAEs or DLTs in all pediatric, adolescent and adult patients treated (high dose, n=6; low dose, n=4) across both REVEAL trials as of February 2025 data cutoff Completed dosing of the 10 patients in Part A of both REVEAL trials; maturing dataset continues to support advancement toward pivotal Part B trial Productive ongoing discussions with the FDA to solidify regulatory pathway for TSHA-102; upda

GlobeNewswire 3 months ago

TSHA
+0.36%
Taysha Gene Therapies to Release Full-Year 2024 Financial Results and Host Conference Call and Webcast on February 26

DALLAS, Feb. 19, 2025 (GLOBE NEWSWIRE) -- Taysha Gene Therapies, Inc. (Nasdaq: TSHA), a clinical-stage biotechnology company focused on advancing adeno-associated virus (AAV)-based gene therapies for severe monogenic diseases of the central nervous system (CNS), today announced that it will report its financial results for the full-year ended December 31, 2024, and host a corporate update conference call and webcast on Wednesday, February 26, 2025, at 8:30 AM Eastern Time. Conference Call Detail

GlobeNewswire 3 months ago

TSHA
+0.36%

Performance Overview

Return	TSHA	S&P 500 (^GSPC)
YTD	+61.27%	+1.52%
1-Year	-24.18%	+12.84%
3-Year	+1.82%	+45.33%

News

Life

Entertainment

Finance

Sports

New on Yahoo

Yahoo Finance

Taysha Gene Therapies, Inc. (TSHA)

Taysha Gene Therapies Announces Details for Oral Presentations at the 2025 IRSF Rett Syndrome Scientific Meeting Reviewing Recent Updates from the TSHA-102 Clinical Program

Taysha Gene Therapies, Inc. (TSHA)’s TSHA-102 Shows Promising Results in Rett Syndrome Patients Aged 6+

Taysha Gene Therapies Announces Pricing of Public Offering of Common Stock and Pre-Funded Warrants

Taysha Gene Therapies Announces Proposed Public Offering of Common Stock and Pre-Funded Warrants

Taysha Gene Therapies Announces Pivotal Part B Trial Design Details for TSHA-102 in Rett Syndrome Enabled by IRSF Natural History Data and Positive Clinical Data from Part A of the REVEAL Adult/Adolescent and Pediatric Trials Evaluating TSHA-102

Taysha Gene Therapies Inc (TSHA) Q1 2025 Earnings Call Highlights: Promising Clinical Progress ...

Taysha Gene Therapies, Inc. (TSHA) Reports Q1 Loss, Tops Revenue Estimates

Taysha Gene Therapies Reports First Quarter 2025 Financial Results and Provides Corporate Update

Taysha Gene Therapies to Release First Quarter 2025 Financial Results and Host Conference Call and Webcast on May 15

Will Taysha Gene Therapies, Inc. (TSHA) Report Negative Q1 Earnings? What You Should Know

Assembly Biosciences (ASMB) Soars 24.0%: Is Further Upside Left in the Stock?

Taysha Gene Therapies Announces Inducement Grant Under Nasdaq Listing Rule 5635(c)(4)

Discover Fractyl Health And 2 More Promising Penny Stocks

Biotech stocks slide as Marks resignation seen being negative for sector

Is Taysha Gene Therapies (TSHA) the Best Short Squeeze Stock to Buy According to Analysts?

Nano Dimension And 2 Other Penny Stocks To Watch Now

Taysha Gene Therapies Full Year 2024 Earnings: Beats Expectations

Taysha Gene Therapies, Inc. (TSHA) Reports Q4 Loss, Tops Revenue Estimates

Taysha Gene Therapies Reports Full-Year 2024 Financial Results and Provides Corporate Update

Taysha Gene Therapies to Release Full-Year 2024 Financial Results and Host Conference Call and Webcast on February 26

Performance Overview